WHO calls on public for ideas to rename monkeypox
‘Poxy McPoxface’, ‘TRUMP-22’, and ‘Mpox’ are just some of the suggestions submitted by the public
The World Health Organisation (WHO) is asking for the public’s help in renaming the monkeypox virus due to concerns over misconceptions associated with the current name.
Disease names are often chosen behind closed doors by a technical committee, but the WHO has this time decided to open up the process to the public.
There have been recent calls for the disease to be renamed, with critics calling it misleading since monkeys are not the original animal host. In June, a group of scientists wrote a position paper calling for a name that was ‘neutral, non-discriminatory and non-stigmatizing'.
‘It's very important we find a new name for monkeypox because this is best practice not to create any offence to an ethical group, a region, a country, an animal etc,’ WHO spokesperson Fadela Chaib said on Tuesday.
So far, dozens of suggestions have been submitted through the WHO’s online portal. These range from technical (OPOXID-22), to political (TRUMP-22), to light-hearted (Poxy McPoxface). One of the more popular submissions so far is Mpox, submitted by Samuel Miriello, the director of a men's health organisation in Canada.
After convening a group of global experts on August 8, the WHO also decided to rename the two dominant variants of monkeypox. Previously called the Central African or Congo Basin clade and the West African clade, the strains will now be officially called Clade I and Clade II, respectively. The group also decided that Clade II consists of two distinct subclades.
The WHO said it would decide between the proposals based on ‘their scientific validity, their acceptability, their pronounceability (and) whether they can be used in different languages’.
Monkeypox is a viral infection that spreads through close contact and can be identified by flu-like symptoms, distinctive rashes and lesions on the skin. The World Health Organisation (WHO) designated the outbreak as a public health emergency of international concern in late July after cases of the disease were recorded in more than 80 countries where it is not usually found.
Related News
-
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News CPHI Milan Speaker Spotlight: CDMO relations with Pharma and Start-Ups
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News Women in Pharma: Advocating for trans healthcare in pharma
In our monthly series on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance